Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-amyloid PET/CT for Monitoring Therapeutic Response in Light Chain Cardiac Amyloidosis
NCT07829705Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2020
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
A Phase 2 trial of carbon-11 Pittsburgh compound B, Florbetapir in immunoglobulin light-chain amyloidosis (AL), sponsored by Peking Union Medical College Hospital. Started Jun 2020; status: recruiting.
02
Drugs
carbon-11 Pittsburgh compound BFlorbetapir
03
Conditions
immunoglobulin light-chain amyloidosis (AL)
Beyond the preview
Go deeper on NCT07829705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829705.